Actively Recruiting

Age: 12Years +

All Genders

ID06213974

Post Authorization Study to Monitor Efficacy, Effectiveness, and Safety of Maribavir LIVTENCITY in Patients With Post-transplant Cytomegalovirus CMV Infection in Argentina

Led by Takeda

Updated on 2026-06-04

10

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

Brief Title

Who Can Participate

AI-Screening

Your Study Journey

Trial Site Locations

Research Team

How is the study designed?

Similar Trials

Frequently Asked Questions

AI-Summary

What This Trial Is About

This research aims to understand the safety and effectiveness of Maribavir in adults and children aged 12 and older who have post-transplant cytomegalovirus CMV infection in routine clinical practice in Argentina. The study collects real-world data from medical records and during the conduct of the study to evaluate how Maribavir is used and its impact in this patient group.



Participants include those who have received Maribavir treatment either after its marketing authorization or before through expanded access or compassionate use programs. Data will be collected both prospectively and retrospectively over an observation period of 16 weeks to monitor treatment outcomes and safety. During the study, participants will be monitored for adverse events from the start of treatment up to week 16. Researchers will also measure the clearance of CMV DNA in plasma, symptom control of CMV infection, and clinically relevant responses to treatment at weeks 8 and 16. The study involves no intervention beyond standard care, and all data are gathered through routine clinical practice observations.

CONDITIONS

Brief Title

A Study of Maribavir in Adults and Children With Post-transplant Cytomegalovirus (CMV) Infection in Argentina

Who Can Participate

Age: 12Years +

All Genders

Eligibility Criteria

You may qualify if you...

Adult participants (18 years or older) and pediatric participants (12 years of age an

📌 Post Authorization Study To Monitor Efficacy, Effectiveness, And Safety Of Maribavir LIVTENCITY In Patients With Post-Transplant Cytomegalovirus CMV Infection In Argentina (Buenos Aires)
🏢 DecenTrialz
📍 Buenos Aires